Neoadjuvant Eribulin Mesylate Following Anthracycline and Taxane in Triple Negative Breast Cancer: Results From the HOPE Study

PLoS ONE - United States
doi 10.1371/journal.pone.0220644
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

PIK3CA H1047R Mutation Associated With a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated With Anthracycline-Taxane–Based Neoadjuvant Chemotherapy

Cancer Research and Treatment
Cancer ResearchOncology
2020English

Eribulin Mesylate in the Treatment of Metastatic Breast Cancer

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2012English

Triple-Negative Breast Cancer

2018English

Comparative Analysis of Different Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer

Tumors of female reproductive system
2017English

Combination Chemotherapy of Mitomycin C and Methotrexate Was Effective on Metastatic Breast Cancer Resistant to Eribulin, Vinorelbine, and Bevacizumab After Anthracycline, Taxane, and Capecitabine

Case Reports in Oncology
Oncology
2016English

Evolving Approaches to Metastatic Breast Cancer Patients Pre-Treated With Anthracycline and Taxane

BioDrugs
MedicineBiotechnologyPharmacology
2013English

A Phase II Study of Gemcitabine Monotherapy in Breast Cancer Patients Refractory to Anthracycline and Taxane

Cancer Research and Treatment
Cancer ResearchOncology
2002English

Risk Factors Affecting Breast Cancer-Related Lymphedema: Serial Body Weight Change During Neoadjuvant Anthracycline Plus Cyclophosphamide Followed by Taxane

Clinical Breast Cancer
Cancer ResearchOncology
2018English

Triple Negative Breast Cancer: Breast Cancer Research in Evolution

Breast Disease
MedicineCancer ResearchOncology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy